SFC news published since 2018. See SFC archived content for earlier news articles.
Ageing populations, resource constraints and the need for environmentally-sustainable manufacturing processes are just some of the challenges facing the pharmaceutical industry today.
The Medicines Manufacturing Innovation Centre Glasgow aims to address these challenges by developing the medicines manufacturing processes of the future, enabling a more agile, responsive medicines supply chain through improved manufacturing processes.
The Centre is collaboration between the University of Strathclyde-led Centre for Continuous Manufacturing and Crystallisation (CMAC), CPI, AstraZeneca, GlaxoSmithKline and Scottish Enterprise and UKRI.
The consortium aims to develop the medicines manufacturing processes of the future, enabling a more agile, responsive medicines supply chain through improved manufacturing processes. It will enable new and disruptive technologies to be proven at scale in a Global Manufacturing Practice environment. This will allow the rapid adoption of next-generation processes that reduce risk, cut costs and save time, enabling a healthier society and a robust UK economy.
The Centre is a purpose-built £35m facility, currently under construction next to Glasgow International Airport in the Advanced Manufacturing Innovation District Scotland (AMIDS). In the first five years of its operation, the Centre is expected to support over 100 jobs and generate £200m investment in advanced technologies.
The Centre is already delivering three ‘Grand Challenges’. The first, in collaboration with CMAC, is exploring how oral solid dosage medicines can be produced more robustly and efficiently. The second focuses on how these medicines can then be delivered to patients with minimal waste and maximum speed. The third will help overcome barriers to the scalable, affordable, and sustainable manufacture of oligonucleotides.
